Northern Exposure PR

We are the leading public relations company serving the life science, pharmaceutical and technology industries.

Northern Exposure is the leading public relations company serving the life science, pharmaceutical and technology industries.

Twenty years experience maximising clients’ media exposure and advising on subjects from press handling, marketing strategy and reputation management

Northern Exposure Public Relations  is uniquely skilled in assisting clients in all public relations requirements

Meet Our Team


Richard Kerns

Richard Kerns

Managing Director

Richard has twenty five years’ experience working with life science companies and organisations around the globe, both independently and within larger agencies.

Edward Dutton

Edward Dutton

Vice President

Ed has over fifteen years experience of working within the pharmaceutical industry, both as a laboratory chemist and in sales and marketing roles within contract research organisations, contract manufacturers and technology based companies.

Sarah Houlton

Sarah Houlton

Technical Consultant in Residence

Sarah has a degree and PhD in chemistry from Imperial College London, and worked as a drug discovery chemist in the pharmaceutical industry. As a science journalist, she has been writing about the pharmaceutical, biotech and chemical industries for more than twenty years.

Our Services

NEPR can assist clients in numerous manners, either on a retained agency basis or through project work around events. Activities include:

Planning & research, web content creation, media relations, technical articles, thought leadership articles, trade show and event management and support, social media, product launches, crisis management & more. 

Contact us today to find out how we can assist you

Our Clients

Client News

04/01/2019 Catalent Invests $200 Million to Expand Biologics Capacity and Capabilities

12/02/2019 SGS to Conduct its First Malaria Human Challenge Trial in Belgium

13/02/2019 Catalent Names Alessandro Maselli President and Chief Operating Officer

18/02/2019 Catalent Receives P&G External Business Partner of the Year Award

21/02/2019 Catalent Appoints Kay Schmidt to Executive Leadership Team to Lead New Technical Operations Organization

07/03/2019 Catalent Invests Over $27 Million to Commercialize Zydis® Ultra, a Next Generation Oral Disintegrating Tablet

12/03/2019 Successful Phase 2 Clinical Trial Results with Novel Influenza Vaccine Validate SGS’s H3N2 Challenge Agent (A/Belgium)

14/03/2019 Cambrex Completes Expansion and Manufacturing Capability Upgrades in Milan

21/03/2019 Catalent Signs CEO Action for Diversity and Inclusion Pledge

01/04/2019 Triphase Accelerator Initiates Phase 1 Clinical Trial of TRPH-222 in B-cell Lymphoma

04/04/2019 Catalent Expands OptiMelt® Hot Melt Extrusion Capabilities at Somerset Drug Development Center of Excellence

10/04/2019 Cambrex Completes Highly Potent API Manufacturing Facility at Charles City, IA

11/04/2019 Catalent Celebrates Opening of Second Shanghai Facility to Optimize Global and Local Clinical Supply Solutions for China

15/04/2019 Catalent to acquire gene therapy leader Paragon Bioservices, Inc. for $1.2 billion

23/04/2019 Cambrex Completes New Quality Control Laboratory for Generic API Development in Milan

23/04/2019 Catalent Invests $14 Million at its Eberbach, Germany Softgel Facility

25/04/2019 Catalent Collaborates with MGB Biopharma to Provide Accelerated Formulation and Supply Services for Phase 2 Clinical Trial Materials

30/04/2019 SGS Implements Veeva Vault Clinical Trial Management System Across its Global Network

07/05/2019 Catalent Receives RoSPA Silver Award for its Health and Safety Practices

07/05/2019 SGS Recognized at 2019 CRO Leadership Awards for Capabilities, Compatibility, Quality, Expertise and Reliability

09/05/2019 Catalent Achieves Global ISO Accreditation

20/05/2019 Catalent Completes Acquisition of Gene Therapy Leader Paragon Bioservices, Inc. for $1.2 Billion

23/05/2019 Catalent to Launch OneBio Suite for Integrated Biologics Development, Manufacturing and Supply at BIO International 2019

04/06/2019 Cambrex Completes New Process and Analytical Development Facility at its Karlskoga, Sweden Manufacturing Site

17/06/2019 IVERIC bio Enters into Strategic Manufacturing Relationship with Catalent’s Paragon Gene Therapy for Orphan Inherited Retinal Diseases

19/06/2019 Catalent to Purchase Bristol-Myers Squibb Manufacturing Facility in Anagni, Italy

09/07/2019 Catalent Extends Global Commercial Spray Drying Capabilities in Europe

16/07/2019 Catalent Biologics Announces Agreement to Provide Additional Production of Approved Gene Therapy Treatment for Spinal Muscular Atrophy

30/07/2019 Cambrex to Double Size of Edinburgh Solid Form Screening Facility

07/08/2019 Cambrex to be Acquired by the Permira Funds for $60.00 per Share in Cash

23/08/2019 SGS Life Sciences Shortlisted as Finalist in 2019 Clinical Research News European Innovations Awards

05/09/2019 Catalent to Open New Clinical Supply Facility in San Diego

12/09/2019 Catalent Announces the Appointment of David Schaffer to Biologics Advisory Board

17/09/2019 SGS Appoints Steven Thys as Director of Global Clinical Operations

24/09/2019 Catalent and Minerva Neurosciences Enter Commercial Supply Agreement for Schizophrenia Drug Roluperidone

02/10/2019 IDEXX Water Appoints Fisher Scientific channel, part of Thermo Fisher Scientific, as Distributor of Microbiology Testing Products in the EMEA Region for Industrial Markets

03/10/2019 Catalent Appoints Dr. Guy Dewil as General Manager of its Clinical Supply Facility in Schorndorf, Germany

04/11/2019 Catalent Biologics Launches GPEx® Boost Cell Line Expression Technology to Improve Titers and Cell-Specific Productivity

06/11/2019 Catalent’s Chair & Chief Executive Officer, John Chiminski, Receives First Ever ‘Lifetime Achievement’ Award at CPhI Worldwide

14/11/2019 Cambrex Wins Third API Development Award at CPhI Worldwide

19/11/2019 Catalent Appoints Corporate Development and Science Leaders to Drive Growth and Innovation

21/11/2019 Catalent to Supply BeiGene’s BTK Inhibitor BRUKINSA™ (zanubrutinib)

03/12/2019 Catalent to Partner with Ethicann on New Fast-Dissolve Cannabinoid-Based Treatment for Multiple Sclerosis Spasticity

04/12/2019 Cambrex Announces Completion of Acquisition by the Permira Funds

Upcoming Events

NEPR will be attending the following events:

CPhI North America

April 30–May 2, 2019

Chicago, IL

Healthcare Estates

October 8 – 9, 2019

Manchester, UK

CPhI Worldwide

November 5 – 7, 2019

Frankfurt, Germany

IDEXX Water UK are braving the heat this weekend to cycle the 60 miles from London to Cambridge for @AmnestyUK Good…
about 1 year ago | @NrthnExposurePR